Company

Company

The Aenova Group is a leading global contract manufacturer and development services provider for the pharmaceutical and healthcare industry. Our services include end-to-end manufacturing and development of all dosage forms and potency levels (ranging from nutraceuticals to high-potents) out of 15 sites in Europe and the US.

With our comprehensive know-how, many years of experience, well-trained staff of 4.500, innovative technologies and highest quality standards we are a reliable, long-term partner to pharmaceutical and consumer health care customers around the world, both in the human and veterinary healthcare market.

Milestones to a globally leading CDMO

back
2008

2008

Foundation of Aenova Group

Swisscaps Dragenopharm
2008
2021

2020 - 2022

Largest investment program in differentiated technologies/ innovation in corporate history

Chart green
2021
2020

2020

  • Expansion III Tittmoning solids (SOL)
  • Gronau sterile ampoules expansion
Packaging new
2020
2019

2019

  • Complete overhaul of Feldkirchen semi-solids manufacturing site
  • Extension of the soft gel site Cornu
Solids
2019
2018

2018

Divestment of retail business EuroVital Pharma (EVP)

EuroVital Pharma
2018
next
Main corporate events
Main manufacturing/services events

Aenova was created 2008, as a merger of pharmaceutical companies Dragenopharm and Swiss Caps, forming the nucleus of the group. In 2012, the Temmler Group was acquired, and at the beginning of 2014 Haupt Pharma was acquired.

Since 2012, Aenova has been owned by the private equity company BC Partners.